BR112021025477A2 - Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia - Google Patents

Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia

Info

Publication number
BR112021025477A2
BR112021025477A2 BR112021025477A BR112021025477A BR112021025477A2 BR 112021025477 A2 BR112021025477 A2 BR 112021025477A2 BR 112021025477 A BR112021025477 A BR 112021025477A BR 112021025477 A BR112021025477 A BR 112021025477A BR 112021025477 A2 BR112021025477 A2 BR 112021025477A2
Authority
BR
Brazil
Prior art keywords
lpc
therapy
formulations
lysophosphatidylcholine
dha
Prior art date
Application number
BR112021025477A
Other languages
English (en)
Inventor
Berg Storsve Andreas
Gazmeno Håti Armend
Finn Myhren
Lotte Skolem
Nils Hoem
Petter-Arnt Hals
Original Assignee
Aker Biomarine Antarctic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aker Biomarine Antarctic As filed Critical Aker Biomarine Antarctic As
Publication of BR112021025477A2 publication Critical patent/BR112021025477A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia. a presente invenção refere-se às formulações farmacêuticas de fosfolipí-dios e, em particular, formulações farmacêuticas que são administradas por via in-travascular, tal como por via intravenosa. em particular, a presente invenção fornece composições farmacêuticas para administração intravascular que compreendem compostos derivados de fosfatidilcolina que carregam um ácido graxo de ômega 3 para uso em profilaxia ou terapia.
BR112021025477A 2019-06-20 2020-06-21 Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia BR112021025477A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864073P 2019-06-20 2019-06-20
PCT/EP2020/067263 WO2020254675A1 (en) 2019-06-20 2020-06-21 Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy

Publications (1)

Publication Number Publication Date
BR112021025477A2 true BR112021025477A2 (pt) 2022-03-03

Family

ID=71138732

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025477A BR112021025477A2 (pt) 2019-06-20 2020-06-21 Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia

Country Status (11)

Country Link
US (1) US20230038627A1 (pt)
EP (1) EP3986418A1 (pt)
JP (1) JP2022537366A (pt)
KR (1) KR20220049506A (pt)
CN (1) CN114286680A (pt)
AU (1) AU2020298105A1 (pt)
BR (1) BR112021025477A2 (pt)
CA (1) CA3143586A1 (pt)
IL (1) IL289096A (pt)
MX (1) MX2021015311A (pt)
WO (1) WO2020254675A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521598A (ja) 2020-03-31 2023-05-25 エーケル バイオマリーン アンタークティク エーエス Ｌｐｃ－ｄｈａおよびｌｐｃ－ｅｐａが豊富なクリルオイル組成物
WO2022101678A2 (en) 2020-11-15 2022-05-19 Aker Biomarine Antarctic As Lysophospholipid formulations
WO2022125684A1 (en) * 2020-12-08 2022-06-16 Orochem Technologies Inc. Process for purifying lpc-dha and/or lpc-epa using a chromatographic stationary phase and compositions thereof
WO2023081388A1 (en) * 2021-11-05 2023-05-11 The Feinstein Institutes For Medical Research Lysophosphatidylcholine combinations as a therapy to treat cardiac arrest
CN115531399A (zh) * 2022-09-15 2022-12-30 首都医科大学 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068413A2 (fr) 2006-11-14 2008-06-12 INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (INSA de Lyon) Procede de preparation d'acetyl, docosahexaenoyl-glycérophosphocholine, et son utilisation pour l'apport d'acides gras polyinsatures
EP2488190B1 (en) 2009-10-13 2017-09-20 DSM IP Assets B.V. Reducing the risk of pathological effects of traumatic brain injury
KR101951933B1 (ko) 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
EP3049429B1 (en) * 2013-09-26 2020-05-06 National University of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
FR3038606B1 (fr) * 2015-07-06 2018-10-05 Institut National Des Sciences Appliquees De Lyon Glycerophosphocholines, pour leur utilisation dans le traitement d'une inflammation intestinale ou d'un cancer intestinal
FR3063645B1 (fr) 2017-03-08 2021-06-11 Lipther Acefapc pour le traitement des maladies acetylcholine dependantes
US10555957B2 (en) * 2017-05-10 2020-02-11 The Board Of Trustees Of The University Of Illinois Methods and compositions for enriching DHA levels in the brain
JP2021508343A (ja) 2017-12-21 2021-03-04 エーケル バイオマリーン アンタークティク エーエス リゾホスファチジルコリン組成物

Also Published As

Publication number Publication date
IL289096A (en) 2022-02-01
EP3986418A1 (en) 2022-04-27
AU2020298105A1 (en) 2022-01-20
WO2020254675A1 (en) 2020-12-24
JP2022537366A (ja) 2022-08-25
CN114286680A (zh) 2022-04-05
CA3143586A1 (en) 2020-12-24
MX2021015311A (es) 2022-02-21
KR20220049506A (ko) 2022-04-21
US20230038627A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112021025477A2 (pt) Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
SV2018005715A (es) Derivados de 4-amino-2-(1h- pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
CL2020000747A1 (es) Formulaciones de niraparib.
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BR112017018643A2 (pt) "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas"
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112023021160A2 (pt) Lipídeos ionizáveis e composições para liberação em ácido nucleico
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia